微信关注
China
Total item
Cart Subtotal
￥ 0.00 “mul”的搜索结果
-
ML-9 hydrochloride
Catalog No. A17856 MLCK inhibitorML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity. ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively. ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation. 了解更多 -
Ilorasertib
Catalog No. A20982 ATP-competitive multitargeted kinase inhibitorIlorasertib (ABT-348) is a potent and ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora C, Aurora B, and Aurora A with IC50s of 1 nM, 7 nM, 120 nM, respectively. 了解更多 -
Tesevatinib
Catalog No. A21875 multi-target tyrosine kinase inhibitorTesevatinib (XL-647; EXEL-7647; KD-019) is an orally available, multi-target tyrosine kinase inhibitor; inhibits EGFR, ErbB2, KDR, Flt4 and EphB4 kinase with IC50s of 0.3, 16, 1.5, 8.7, and 1.4 nM. 了解更多 -
Rigosertib
Catalog No. A21868 multi-kinase inhibitorRigosertib (ON-01910) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3 kinase/Akt pathway, promots the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle. 了解更多 -
Rigosertib sodium
Catalog No. A21824 multi-kinase inhibitorRigosertib sodium (ON-01910 sodium) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3K/Akt pathway, promotes the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle. 了解更多 -
CPI-0610 carboxylic acid
Catalog No. A21714 BET inhibitorCPI-0610 carboxylic acid is a potent bromodomain and extra-terminal (BET) protein inhibitor. CPI-0610 carboxylic acid has the potential in the therapy of multiple myeloma. 了解更多 -
(R)-BAY1238097
Catalog No. A21593 BET binding to histones inhibitor(R)-BAY1238097 is the R-isomer with lower activity of BAY1238097. BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome. 了解更多 -
cis-Pralsetinib
Catalog No. A21586 RET inhibitorcis-Pralsetinib (cis-BLU-667) is a highly potent and selective inhibitor of rearranged during transfection (RET), with IC50s ranging from 0.3 to 0.4 nM for WT RET and four enzyme variants (V804L, V804M, M918T, CCDC6-RET), and with broad, robust and anti-tumor activity against multiple RET-driven solid tumor types. 了解更多 -
ENMD-2076 Tartrate
Catalog No. A21583 multi-targeted kinase inhibitorENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively. 了解更多 -
BMS-983970
Catalog No. A21547 pan-Notch inhibitorBMS-983970 is an oral pan-Notch inhibitor for the treatment of multiplecancers. 了解更多 -
Amuvatinib hydrochloride
Catalog No. A21503 multi-targeted tyrosine kinase inhibitorAmuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. 了解更多 -
Sorafenib (D4)
Catalog No. A21495 multikinase inhibitorSorafenib D4 (Bay 43-9006 D4) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively. 了解更多 -
Sorafenib (D3)
Catalog No. A21489 multikinase inhibitorSorafenib D3 (Bay 43-9006 D3) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively. 了解更多 -
Galidesivir hydrochloride
Catalog No. A20930 RdRp inhibitorGalidesivir hydrochloride (BCX 4430 hydrochloride) is a viral RNA-dependent RNA polymerase (RdRp) inhibitor; demonstrated broad-spectrum activity in multiple viruses and a favorable preliminary preclinical safety profile. 了解更多 -
Lenvatinib mesylate
Catalog No. A17567 multi-targeted tyrosine kinase inhibitorLenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities. 了解更多 -
SU14813 maleate
Catalog No. A11556 multi-targeted receptor tyrosine kinases inhibitorSU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT. 了解更多 -
Regorafenib Hydrochloride
Catalog No. A11546 VEGFR1/2/3/PDGFRβ/Kit/RET/Raf-1 inhibitorRegorafenib Hydrochloride is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively. 了解更多 -
Pim1/AKK1-IN-1
Catalog No. A11476 multi-kinase inhibitorPim1/AKK1-IN-1 is a potent multi-kinase inhibitor with Kd values of 35 nM/53 nM/75 nM/380 nM for Pim1/AKK1/MST2/LKB1 respectively, and also inhibits MPSK1 and TNIK. 了解更多 -
Cabozantinib S-malate
Catalog No. A11349 multiple receptor tyrosine kinases inhibitorCabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively. 了解更多 -
Cenisertib
Catalog No. A11262 multi-kinase inhibitorCenisertib (AS-703569) is a multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. 了解更多 -
GENZ-882706
Catalog No. A12484 CSF-1R InhibitorGENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor extracted from patent WO 2017015267A1. 了解更多 -
Tyrosine kinase-IN-1
Catalog No. A12486 multi-targeted tyrosine kinase inhibitorTyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC50s of 4, 20, 4, 2 nM for KDR, Flt-1, FGFR1 and PDGFRα, respectively. 了解更多 -
P-gp inhibitor 1
Catalog No. A13384 P-gp inhibitorP-gp inhibitor 1 is a novel inhibitor reversing P-glycoprotein-mediated multidrug resistance. 了解更多 -
Edicotinib
Catalog No. A13008 CSF-1 receptor inhibitorEdicotinib is a selective and orally available colony-stimulating factor-1 (CSF-1) receptor inhibitor, and has entered phase IIA clinical trial to study rheumatoid arthritis (RA) despite disease. 了解更多 -
Lestaurtinib
Catalog No. A11274 multi-kinase inhibitorLestaurtinib (CEP-701;KT-5555) is a multi-kinase inhibitor with potent activity against the Trk family of receptor tyrosine kinases. Lestaurtinib inhibits JAK2, FLT3 and TrkA with IC50s of 0.9, 3 and less than 25 nM, respectively. 了解更多 -
Conteltinib
Catalog No. A13037 multi-kinase inhibitorConteltinib (CT-707) is a multi-kinase inhibitor targeting FAK, ALK, and Pyk2. Conteltinib (CT-707) exerts significant inhibitory effect on FAK with an IC50 of 1.6 nM. 了解更多 -
MMSET-IN-1
Catalog No. A18860 SET domain inhibitorMMSET-IN-1 is a multiple myeloma SET domain (MMSET, aka NSD2/WHSC1) inhibitor against SETD2 and MMSET with IC50s of 0.49 and 3.3 μM, respectively. MMSET-IN-1 has a Kd of 1.6 μM for MMSET. 了解更多 -
c-Fms-IN-8
Catalog No. A18879 CSF-1R, c-FMS Type II inhibitorc-Fms-IN-8 (compound 4a) is a colony stimulating factor-1 receptor (CSF-1R, c-FMS) Type II inhibitor, with an IC50 of 9.1 nM. 了解更多 -
c-Fms-IN-10
Catalog No. A19017 FMS inhibitorc-Fms-IN-10 is the derivative of thieno [3,2-d] pyrimidine, an kinase inhibitor of FMS (Colony stimulating factor-1 receptor, CSF-1R) with IC50 of 2 nM. c-Fms-IN-10 has anti-tumor activity. 了解更多 -
JTE-952
Catalog No. A18391 CSF-1R 抑制剂TE-952 is a potent, oral active and selective Type II inhibitor of colony stimulating factor-1 receptor (CSF-1R or cFMS, type III receptor tyrosine kinase), with IC50 values of 13 nM and 261 nM for CSF1R and TrkA , respectively. Effective against a mouse collagen-induced model of arthritis. 了解更多 -
VP3.15
Catalog No. A18538 dual PDE7/GSK-3 inhibitorVP3.15 is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC50s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS). 了解更多 -
DRI-C21045
Catalog No. A18773 CD40-CD40L inhibitorDRI-C21045 is a potent and selective inhibitor of the CD40-CD40L costimulatory protein-protein interaction (PPI) with an IC50 of 0.17 ?M. 了解更多 -
Promazine hydrochloride
Catalog No. A17638 D2DR inhibitorPromazine Hydrochloride is a phenothiazine compound and D2DR inhibitor. Promazine Hydrochloride has been employed in studies investigating dopamine-stimulated glycosylation of brain proteins in vitro. It has actions similar to chlorpromazine but with less antipsychotic activity. 了解更多 -
Abrocitinib (PF-04965842)
Catalog No. A18318 JAK1 抑制剂Abrocitinib (PF-04965842) is a potent, orally active and selective JAK1 inhibitor, with IC50s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842) exhibits less active effect on TYK2 (IC50, 1.253 μM), and inhibits phosphorylation of STAT1, STAT3 and STAT5 after stimulation. Effective in autoimmune disease. 了解更多
联系我们
United StatesAdooq Bioscience
Toll Free: (866) 930-6790
Fax: +1-323-606-8156
Email: sales@adooq.com
Not your Region? View all Distributors
FILTER BY:
Filtering:
- 作用机制: Inhibitor (抑制剂) 删除该内容
购物选项
- 分类
-
- Epigenetics (4)
- Apoptosis (4)
- PI3K / Akt / mTOR (3)
- Protein Tyrosine Kinases (9)
- Angiogenesis (4)
- MAPK (1)
- JAK / Stat (4)
- Cell Cycle (1)
- Cell Metabolism (1)
- Immunology & Inflammation (1)
- GPCR / G Protein (3)
- TGF-β / Smad (1)
- Neuronal Signaling (1)
- Proteases (1)
- Microbiology (1)
- Stem Cells / Wnt (1)
- Membrane Transporters/Ion Channels (1)
- Others (1)
- Ready to Use Solution (1)
- Products On Sale (3)
- 靶点
ADOOQ 产品质量保证
We promise all products to perform as described.